Zacks cites the company for its technology, products, and meeting its targets.
The share of Bio-Light Israeli Life Sciences Investments Ltd. (TASE:BOLT; Bulletin Board: BLGTY) shot up today on a lively turnover, following an “Outperform” recommendation from Zacks economists. The current share price on Wall Street is $3.79, but Zacks set a target price of $14, 270% higher than the market price.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
Zacks cites Biolight’s ophthalmological technology and products for cancer, which it said fulfill a huge market need, and the company’s consistent meeting of its targets to date.
The group is strengthened by its clusters structure, which constitutes a competitive advantage in generating great interest and significant value in the global market, contains potential for a short time-to-market for its products, and brings cooperation with leading companies in the sector closer in the near future.
In addition, similar deals with substantial value have been made by companies with technologies in the company’s fields of activity, especially intraocular implant technologies for controlled release of eye drops and diagnosis and monitoring of dry eye syndrome.
Zacks also cites the company’s focus on the Asian market, especially China, for a laser-based product that facilitates a unique surgical procedure for treatment of glaucoma without penetrating the inner eye, saying that there is significant market potential there in glaucoma treatment.
Published by Globes [online], Israel business news – www.globes-online.com